

Status: Currently Official on 13-Feb-2025  
Official Date: Official as of 01-Feb-2024  
Document Type: USP Monographs  
DocId: GUID-0BC00AF2-9665-4BDB-9081-5DB9156B534A\_6\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M360\\_06\\_01](https://doi.org/10.31003/USPNF_M360_06_01)  
DOI Ref: q3jls

© 2025 USPC  
Do not distribute

## Acetazolamide Tablets

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click [www.uspnf.com/rb-acetazolamide-tabs-20240126](http://www.uspnf.com/rb-acetazolamide-tabs-20240126).

### DEFINITION

Acetazolamide Tablets contain NLT 95.0% and NMT 105.0% of the labeled amount of acetazolamide ( $C_4H_6N_4O_3S_2$ ).

### IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#):** 197K

**Sample:** Extract a quantity of finely powdered Tablets, equivalent to about 500 mg of acetazolamide, with 50 mL of [acetone](#). Filter, and add sufficient [solvent hexane](#) to the filtrate to cause formation of a heavy, white precipitate. Collect the precipitate on a medium-porosity, sintered-glass funnel, and dry with suction.

**Acceptance criteria:** Meet the requirements

- B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### PROCEDURE

**Mobile phase:** Dissolve 4.1 g of [anhydrous sodium acetate](#) in 950 mL of [water](#), add 20 mL of [methanol](#) and 30 mL of [acetonitrile](#), and mix. Adjust with [glacial acetic acid](#) to a pH of 4.0.

**Standard solution:** 0.1 mg/mL of [USP Acetazolamide RS](#) prepared as follows. Transfer [USP Acetazolamide RS](#) into a suitable volumetric flask, add 0.5 N [sodium hydroxide](#) equivalent to 10% of the final volume, and dilute with [water](#) to volume.

**Sample stock solution:** Nominally equivalent to 1.0 mg/mL of acetazolamide prepared as follows. Transfer a portion of the powder, from NLT 20 Tablets, equivalent to 100 mg acetazolamide into a 100-mL volumetric flask. Add 10 mL of 0.5 N [sodium hydroxide](#), sonicate for 5 min, cool to room temperature, and dilute with [water](#) to volume. Filter a portion of this solution, discarding the first 20 mL of the filtrate.

**Sample solution:** Nominally equivalent to 0.1 mg/mL of acetazolamide prepared as follows. Transfer 10.0 mL of *Sample stock solution* and 10 mL of 0.5 N [sodium hydroxide](#) to a 100-mL volumetric flask, and dilute with [water](#) to volume.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; packing [L1](#)

**Flow rate:** 2 mL/min

**Injection volume:** 20 µL

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 1.5

**Relative standard deviation:** NMT 1.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acetazolamide ( $C_4H_6N_4O_3S_2$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = acetazolamide peak response from the *Sample solution*

$r_S$  = acetazolamide peak response from the *Standard solution*

$C_S$  = concentration of [USP Acetazolamide RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of acetazolamide in the *Sample solution* (mg/mL)

**Acceptance criteria:** 95.0%–105.0%

**PERFORMANCE TESTS****Change to read:**

- [DISSOLUTION \(711\)](#).

**▲Test 1▲** (RB 1-Feb-2024)

**Medium:** 0.01 N [hydrochloric acid](#); 900 mL

**Apparatus 1:** 100 rpm

**Time:** 60 min

**Standard solution:** [USP Acetazolamide RS](#) in *Medium*

**Sample solution:** Dilute with *Medium* if necessary.

**Instrumental conditions**

(See [Ultraviolet-Visible Spectroscopy \(857\)](#).)

**Mode:** UV

**Analytical wavelength:** 265 nm

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Determine the percentage of the labeled amount of acetazolamide ( $C_4H_6N_4O_3S_2$ ) dissolved:

$$(A_U/A_S) \times C_S \times D \times (V/L) \times 100$$

$A_U$  = absorbance of the *Sample solution*

$A_S$  = absorbance of the *Standard solution*

$C_S$  = concentration of the *Standard solution* (mg/mL)

$D$  = dilution factor of the *Sample solution*, if needed

$V$  = volume of *Medium*, 900 mL

$L$  = label claim (mg/Tablet)

**Tolerances:** NLT 75% (Q) of the labeled amount of acetazolamide ( $C_4H_6N_4O_3S_2$ ) is dissolved.

**▲Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

**Medium:** 0.01 N [hydrochloric acid](#), deaerated, if necessary; 900 mL

**Apparatus 1:** 100 mesh; 100 rpm

**Time:** 20 min

**Standard solution**

**For Tablets labeled to contain 125 mg:** ( $L/900$ ) mg/mL of [USP Acetazolamide RS](#) prepared as follows. Transfer an appropriate quantity of [USP Acetazolamide RS](#) to a suitable volumetric flask, add 10% of the flask volume of [acetonitrile](#), and sonicate to dissolve, if necessary. Dilute with *Medium* to volume.

**For Tablets labeled to contain 250 mg:** ( $L/900$ ) mg/mL of [USP Acetazolamide RS](#) prepared as follows. Transfer an appropriate quantity of [USP Acetazolamide RS](#) to a suitable volumetric flask, add 20% of the flask volume of [acetonitrile](#), and sonicate to dissolve, if necessary. Dilute with *Medium* to volume.

**Sample solution:** Pass through a suitable filter of 0.45- $\mu$ m pore size, discarding an appropriate volume of filtrate so that a consistent result can be obtained.

**Instrumental conditions**

(See [Ultraviolet-Visible Spectroscopy \(857\)](#).)

**Mode:** UV

**Analytical wavelength:** 265 nm

**Cell:** 1 mm

**Blank:** *Medium*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acetazolamide ( $C_4H_6N_4O_3S_2$ ) dissolved:

$$\text{Result} = (A_U/A_S) \times C_S \times V \times (1/L) \times 100$$

$A_U$  = absorbance from the *Sample solution*

$A_S$  = absorbance from the *Standard solution*

$C_S$  = concentration of [USP Acetazolamide RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of the *Medium*, 900 mL

L = label claim (mg/Tablet)

**Tolerances:** NLT 80% (Q) of the labeled amount of acetazolamide (C<sub>4</sub>H<sub>6</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub>) is dissolved.▲ (RB 1-Feb-2024)

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in tight containers, and store at controlled room temperature.

**Add the following:**

- ▲ **LABELING:** The labeling states the *Dissolution* test used only if *Test 1* is not used.▲ (RB 1-Feb-2024)

- [USP REFERENCE STANDARDS \(11\)](#).  
[USP Acetazolamide RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ACETAZOLAMIDE TABLETS	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 42(6)

**Current DocID:** GUID-0BC00AF2-9665-4BDB-9081-5DB9156B534A\_6\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M360\\_06\\_01](https://doi.org/10.31003/USPNF_M360_06_01)

**DOI ref:** [q3jls](#)

OFFICIAL